Emotions and brain function are altered up to one month after a single high dose of psilocybin
In an open‑label pilot with 12 healthy volunteers, a single high dose of psilocybin (25 mg/70 kg) produced transient reductions in negative affect and amygdala reactivity at one week, while increases in positive affect and reduced trait anxiety persisted at one month, accompanied by increased resting‑state functional connectivity. These preliminary results suggest psilocybin enhances emotional and neural plasticity and support targeting negative affect in therapeutic applications.
Authors
- Roland Griffiths
- Frederick Barrett
- Nathan Sepeda
Published
Abstract
Psilocybin is a classic psychedelic compound that may have efficacy for the treatment of mood and substance use disorders. Acute psilocybin effects include reduced negative mood, increased positive mood, and reduced amygdala response to negative affective stimuli. However, no study has investigated the long-term, enduring impact of psilocybin on negative affect and associated brain function. Twelve healthy volunteers (7F/5M) completed an open-label pilot study including assessments 1-day before, 1-week after, and 1-month after receiving a 25 mg/70 kg dose of psilocybin to test the hypothesis that psilocybin administration leads to enduring changes in affect and neural correlates of affect. One-week post-psilocybin, negative affect and amygdala response to facial affect stimuli were reduced, whereas positive affect and dorsal lateral prefrontal and medial orbitofrontal cortex responses to emotionally-conflicting stimuli were increased. One-month post-psilocybin, negative affective and amygdala response to facial affect stimuli returned to baseline levels while positive affect remained elevated, and trait anxiety was reduced. Finally, the number of significant resting-state functional connections across the brain increased from baseline to 1-week and 1-month post-psilocybin. These preliminary findings suggest that psilocybin may increase emotional and brain plasticity, and the reported findings support the hypothesis that negative affect may be a therapeutic target for psilocybin.
Research Summary of 'Emotions and brain function are altered up to one month after a single high dose of psilocybin'
Introduction
Earlier research has shown that psilocybin, a classic 5-HT2A receptor partial agonist, can produce acute reductions in negative mood, increases in positive mood, and decreased amygdala responses to negative emotional stimuli, and small clinical studies suggest antidepressant and anti-addiction effects that can persist for months after one or a few administrations. However, the mechanisms that might underlie any enduring therapeutic effects remain unclear. Two candidate, potentially interacting mechanisms are modulation of negative affect (and related affective biases) and changes in large-scale brain network plasticity; both amygdala reactivity and anterior cingulate cortex (ACC) function figure prominently in models of mood and substance use disorders and in prior psychedelic neuroimaging findings. Barrett and colleagues therefore conducted an open-label, within-subjects pilot study to test whether a single high dose of psilocybin (25 mg/70 kg) produces enduring changes in affect, personality, task-evoked neural responses to emotional stimuli, and resting-state functional connectivity. Participants were assessed one day before, one week after, and one month after psilocybin using a battery of self-report affect and personality measures and functional MRI during three emotion tasks and resting state. The study aimed to determine whether post-acute changes in affect and brain function persist after drug elimination and could point to trans-diagnostic mechanisms relevant to mood and substance use disorders.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Barrett, F. S., Doss, M. K., Sepeda, N. D., Pekar, J. J., & Griffiths, R. R. (2020). Emotions and brain function are altered up to one month after a single high dose of psilocybin. Scientific Reports, 10(1). https://doi.org/10.1038/s41598-020-59282-y
References (42)
Papers cited by this study that are also in Blossom
Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)
Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)
Garcia-Romeu, A., Griffiths, R. R., Johnson, M. W. · Current Drug Abuse Reviews (2015)
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)
Bogenschutz, M. P., Podrebarac, S. K., Duane, J. H. et al. · Frontiers in Pharmacology (2018)
Johnson, M. W., Garcia-Romeu, A., Griffiths, R. R. · The American Journal of Drug and Alcohol Abuse (2016)
Rocha, J. M., Osório, F. L., Crippa, J. A. et al. · Therapeutic Advances in Psychopharmacology (2019)
Kometer, M., Schmidt, A., Bachmann, R. et al. · Biological Psychiatry (2012)
Kraehenmann, R., Preller, K. H., Scheidegger, M. et al. · Biological Psychiatry (2015)
Show all 42 referencesShow fewer
Schmidt, A., Kometer, M., Bachmann, R. et al. · Psychopharmacology (2012)
Dolder, P. C., Schmid, Y., Müller, F. et al. · Neuropsychopharmacology (2016)
Kraehenmann, R., Schmidt, A., Friston, K. et al. · NeuroImage (2015)
Grimm, O., Kraehenmann, R., Preller, K. H. et al. · European Neuropsychopharmacology (2018)
Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)
Carhart-Harris, R. L., Leech, R., Williams, T. M. et al. · British Journal of Psychiatry (2018)
Johnson, M. W., Garcia-Romeu, A., Johnson, P. S. et al. · Journal of Psychopharmacology (2017)
Preller, K. H., Herdener, M., Pokorny, T. et al. · Current Biology (2017)
Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)
Kaelen, M., Giribaldi, B., Raine, J. et al. · Psychopharmacology (2018)
Carhart-Harris, R. L., Leech, R., Shanahan, M. et al. · Frontiers in Human Neuroscience (2014)
Palhano-Fontes, F., Andrade, K. C., Tófoli, L.F. et al. · PLOS ONE (2015)
Roseman, L., Leech, R., Feilding, A. et al. · Frontiers in Human Neuroscience (2014)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Carhart-Harris, R. L., Roseman, L., Bolstridge, M. et al. · Scientific Reports (2017)
Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)
Passie, T., Seifert, J., Schneider, U. et al. · Addiction Biology (2002)
Brown, R. T., Nicholas, C. R., Cozzi, N. V. et al. · Clinical Pharmacokinetics (2017)
Roseman, L., Demetriou, L., Wall, M. B. et al. · Neuropharmacology (2018)
Sampedro, F., de la Fuente Revenga, M., Valle, M. et al. · International Journal of Neuropsychopharmacology (2017)
Studerus, E., Gamma, A., Kometer, M. et al. · PLOS ONE (2012)
Russ, S. L., Carhart-Harris, R. L., Maruyama, G. et al. · Psychology of Consciousness Theory Research and Practice (2019)
Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)
Erritzoe, D., Roseman, L., Nour, M. R. et al. · Acta Psychiatrica Scandinavica (2018)
Griffiths, R. R. · Journal of Psychopharmacology (2008)
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)
Nardou, R., Lewis, E. M., Rothhaas, R. et al. · Nature (2019)
Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)
Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Journal of Psychopharmacology (2017)
Barrett, F. S., Carbonaro, T. M., Hurwitz, E. et al. · Psychopharmacology (2018)
Carbonaro, T. M., Hurwitz, E., Johnson, M. W. · Psychopharmacology (2017)
Cited By (114)
Papers in Blossom that reference this study
Girn, M., Doss, M. K., Roseman, L. et al. · Nature Medicine (2026)
Orłowski, P., Domagalik, A., Bola, M. · Human Brain Mapping (2026)
Henningfield, J. E., Barrett, F. S., Evans, S. M. et al. · Journal of Psychopharmacology (2026)
Garcia-Romeu, A., Naudé, G. P., Rebman, A. W. et al. · Scientific Reports (2026)
Jacobs, E., Zahid, Z., Hinkle, J. et al. · BMJ (2026)
Goldy, S. P., Sepeda, N. D., Hilbert, S. N. et al. · Psychiatry Research (2026)
Mallaroni, P., Singleton, P., Mason, N. L. et al. · Molecular Psychiatry (2026)
Blest-Hopley, G., Pasculli, G., Ruffell, S. G. D. et al. · Frontiers in Psychiatry (2025)
McCulloch, D. E-W., Larsen, K., Johansen, A. et al. · MedRvix (2025)
Wall, M. B., Demetriou, L., Giribaldi, B. et al. · American Journal of Psychiatry (2025)
Show all 114 papersShow fewer
Harding, R., Singer, N., Wall, M. B. et al. · Molecular Psychiatry (2025)
Godfrey, K., Weiss, B., Zhang, X. et al. · Neuroscience Applied (2025)
Shinozuka, K., Jerotic, K., Mediano, P. A. M. et al. · Translational Psychiatry (2024)
Calder, A. E., Hase, A., Hasler, G. · Molecular Psychiatry (2024)
Enriquez-Geppert, S,, Lietz, M. P., O'Higgins, F. · Philosophical Transactions of the Royal Society B (2024)
Lyons, T., Spriggs, M. J., Kerkelä, L. et al. · Biorxiv (2024)
Avram, M., Fortea, L., Wollner, L. et al. · Molecular Psychiatry (2024)
Nicol, G. E. · Nature (2024)
Stoliker, D., Novelli, L., Vollenweider, F. X. et al. · Biological Psychiatry (2024)
Casanova, A. F., Ort, A., Smallridge, J. W. et al. · iScience (2024)
Shinozuka, K., Tewarie, P. K. B., Luppi, A. et al. · Biorxiv (2024)
Weiss, B., Leor Roseman, •., Giribaldi, B. et al. · International Journal of Mental Health and Addiction (2024)
Erritzoe, D., Timmermann, C., Godfrey, K. et al. · Nature Mental Health (2024)
Pagni, B. A., Petridis, P. D., Podrebarac, S. K. et al. · Scientific Reports (2024)
Solaja, I., Haldane, K., Mason, N. et al. · Neuroscience and Biobehavioral Reviews (2024)
Allen, J., Dames, S., Foldi, C. J. et al. · Molecular Psychiatry (2024)
Weiss, B., Sleep, C., Beller, N. et al. · Journal of Psychedelic Studies (2023)
Orłowski, P., Hobot, J., Ruban, A. et al. · Journal of Psychopharmacology (2023)
Enriquez-Geppert, S,, Krc, J., O'Higgins, F., Lietz, M. P. · OSF Preprints (2023)
Mallaroni, P., Mason, N. L., Kloft, L. et al. · Frontiers in Neuroscience (2023)
Jaster, A. M., González-Maeso, J. · Molecular Psychiatry (2023)
Wall, M. B., Harding, R., Zafar, R. et al. · Molecular Psychiatry (2023)
Nayak, S., Jackson, H., Sepeda, N. D. et al. · Frontiers in Psychiatry (2023)
Ramaekers, J. G., Mallaroni, P., Kloft, L. et al. · Journal of Cognitive Neuroscience (2023)
Nikolič, M., Viktorin, V., Zach, P. et al. · European Neuropsychopharmacology (2023)
Peck, S. K., Shao, S., Grue, T. et al. · Nature Medicine (2023)
Goodwin, G. M., Malievskaia, E., Fonzo, G. A. et al. · American Journal of Psychiatry (2023)
McCulloch, D. E-W., Olsen, A. S., Ozenne, B. et al. · MedRvix (2023)
Wall, M. B., Lam, C., Ertl, N. et al. · Journal of Affective Disorders (2023)
Tiwari, P., Sayali, C., Doss, M. K. et al. · Psychedelic Medicine (2023)
Newton, K., Moreton, S. G. · Ecopsychology (2023)
Brasher, T., Rosen, D., Spinella, M. · International Journal of Wellbeing (2023)
Forstmann, M., Kettner, H. S., Sagioglou, C. et al. · Journal of Psychopharmacology (2023)
Breant, B., Mengual, J. P., Bannerman, D. et al. · Biorxiv (2022)
Olsen, A. S., Ozenne, B., Madsen, M. K. et al. · NeuroImage (2022)
Gukasyan, N., Schreyer, C. C., Griffiths, R. R. et al. · Current Psychiatry Reports (2022)
Kwan, A. C., Olson, D. E., Preller, K. H. et al. · Nature Medicine (2022)
Gattuso, J. J., Perkins, D., Ruffell, S. G. D. et al. · International Journal of Neuropsychopharmacology (2022)
Bogenschutz, M. P., Ross, S., Bhatt, S. R. et al. · JAMA Psychiatry (2022)
Calder, A. E., Hasler, G. · Neuropsychopharmacology (2022)
Dourron, H. M., Strauss, C., Hendricks, P. S. · Pharmacological Reviews (2022)
Stoliker, D., Egan, G. F., Friston, K. J. et al. · Pharmacological Reviews (2022)
Bonnelle, V., Cavarra, M., Kryskow, P. et al. · British Journal of Pain (2022)
Knight, G., Rucker, J., Cleare, A. J. et al. · Frontiers in Psychiatry (2022)
Kiraga, M. K., Kuypers, K. P. C., Uthaug, M. V. et al. · Frontiers in Psychiatry (2022)
Belser, A. B. · Frontiers in Psychology (2022)
Doss, M. K., de Wit, H., Gallo, D. A. · Psyarxiv (2022)
Jairaj, C., Rucker, J. · Journal of Psychopharmacology (2022)
Johnson, S., Letheby, C. · Journal of Psychedelic Studies (2022)
Forstmann, M., Sagioglou, C. · European Psychologist (2022)
McCulloch, D. E-W., Knudsen, G. M., Barrett, F. S. et al. · Neuroscience and Biobehavioral Reviews (2022)
Gill, H., Puramat, P., Patel, P. et al. · Psychiatry Research (2022)
Aharon-Almagor, A., Barrett, F. S. · Research Square (2022)
Daws, R. E., Timmermann, C., Giribaldi, B. et al. · Nature Medicine (2022)
Pots, W., Chakhssi, F. · Frontiers in Psychology (2022)
Gandy, S. · Journal of Psychedelic Studies (2022)
Timmermann, C., Watts, R., Dupuis, D. · Transcultural Psychiatry (2022)
McCulloch, D. E-W., Madsen, M. K., Jensen, P. S. et al. · Frontiers in Pharmacology (2022)
Smedfors, G., Glotfelty, E., Papatziamos, C. et al. · Research Square (2022)
Family, N., Hendricks, P. S., Williams, L. T. J. et al. · Journal of Psychopharmacology (2022)
Elman, I., Borsook, D., Pustilink, A. · Neuroscience and Biobehavioral Reviews (2022)
Vollenweider, F. X., Smallridge, J. W. · Pharmacopsychiatry (2022)
Barrett, F. S., Zhou, Y., Carbonaro, T. M. et al. · Frontiers in Neuroergonomics (2022)
Dursun, S. M., Kelly, J. R., Gillan, C. M. et al. · Frontiers in Psychiatry (2021)
Rieser, N. M., Herdener, M. ;., Preller, K. H. · Current Topics in Behavioral Neurosciences (2021)
Whitfield, H. J. · Frontiers in Psychiatry (2021)
Olson, D. E. · Journal of Neurochemistry (2021)
Nygart, V., Pommerencke, L. M., Carhart-Harris, R. L. et al. · Frontiers in Psychology (2021)
Doss, M. K., Považan, M., Rosenberg, M. D. et al. · Translational Psychiatry (2021)
Garcia-Romeu, A., Darcy, S., Jackson, H. et al. · Current Topics in Behavioral Neurosciences (2021)
Rodríguez Arce, J. M., Winkelman, M. J. · Frontiers in Psychology (2021)
McGovern, H., Leptourgos, P., Hutchinson, B. et al. · Psyarxiv (2021)
Castelhano, J. M., Lima, G. M., Teixeira, M. et al. · Frontiers in Pharmacology (2021)
Dos Santos, R. G., Rocha, J. M., Rossi, G. N. et al. · Frontiers in Psychiatry (2021)
Healy, C. J., Lee, K. A. · Chronic Stress (2021)
Rodan, S., Aouad, P., McGregor, I. S. et al. · OBM Neurobiology (2021)
Dos Santos, R. G., Osório, F. L., Rocha, J. M. et al. · Journal of Clinical Psychopharmacology (2021)
Bird, C. I. V., Modlin, N. L., Rucker, J. · International Review of Psychiatry (2021)
Daws, R. E., Timmermann, C., Giribaldi, B. et al. · Research Square (2021)
Davis, A. K., Barrett, F. S., May, D. G. et al. · JAMA Psychiatry (2021)
Rocha, J. M., Rossi, G. N., de Lima Osório, F. et al. · Journal of Clinical Psychopharmacology (2021)
Hesselgrave, N., Troppoli, T. A., Wulff, A. B. et al. · PNAS (2021)
Mason, N. L., Kuypers, K. P. C., Reckweg, J. T. et al. · Translational Psychiatry (2021)
Weiss, B., Miller, J. D., Carter, N. T. et al. · Scientific Reports (2021)
Garcia-Romeu, A., Barrett, F. S., Carbonaro, T. M. et al. · Journal of Psychopharmacology (2021)
McCulloch, D. E-W., Madsen, M. K., Stenbæk, D. S. et al. · Journal of Psychopharmacology (2021)
Williams, T. M., Davis, A. K., Xin, Y. et al. · Drugs Education Prevention and Policy (2020)
Nichols, D. E., Walter, H. · Pharmacopsychiatry (2020)
Gandy, S., Forstmann, M., Carhart-Harris, R. L. et al. · Health Psychology Open (2020)
Dudysová, D., Janků, K., Šmotek, M. et al. · Frontiers in Pharmacology (2020)
Hibicke, M., Gobbi, G. · Journal of Neuroscience (2020)
DiVito, A. J., Leger, R. F. · Molecular Biology Reports (2020)
Brouwer, A., Carhart-Harris, R. L. · Journal of Psychopharmacology (2020)
Goldberg, S. B., Shechet, B., Nicholas, C. R. et al. · Psychological Medicine (2020)
Vollenweider, F. X., Preller, K. H. · Nature Reviews Neuroscience (2020)
Greb, A. C., Vargas, M. V., Duim, W. C. et al. · ACS Pharmacology and Translational Science (2020)
Kelly, J. R., Crockett, M. T., Alexander, L. et al. · Irish Journal of Psychological Medicine (2020)
Aday, J. S., Davoli, C. C., Bloesch, E. K. · Therapeutic Advances in Psychopharmacology (2020)
Davis, A. K., Averill, L. A., Sepeda, N. D. et al. · Chronic Stress (2020)
Jacobs, E. · Journal of Psychedelic Studies (2020)
Nichols, D. E. · Journal of Antibiotics (2020)
Girn, M., Roseman, L., Bernhardt, B. et al. · Biorxiv (2020)
Nutt, D. J., Erritzoe, D., Carhart-Harris, R. L. · Cell (2020)
Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K. et al. · Neuroscience and Biobehavioral Reviews (2020)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.